Son, 11,475 patient aspirin prophylaxis PSM study: 24% lower mortality [p=0.52], 7% higher progression [p=0.8], and 11% more cases [p=0.21] https://c19p.org/son
copied to clipboard
Effect of aspirin on coronavirus disease 2019
et al., Medicine, doi:10.1097/MD.0000000000026670
PSM retrospective case control study in South Korea, showing a trend towards lower mortality, but no significant differences with aspirin use.
|
risk of death, 24.0% lower, OR 0.76, p = 0.52, treatment 37 of 128 (28.9%) cases,
31 of 128 (24.2%) controls, case control OR, group 1, model 2 (most data in group and adjustments).
|
|
risk of progression, 7.0% higher, OR 1.07, p = 0.80, treatment 77 of 339 (22.7%) cases,
58 of 339 (17.1%) controls, case control OR, complications, group 1, model 2 (most data in group and adjustments).
|
|
risk of case, 11.0% higher, OR 1.11, p = 0.21, treatment 313 of 3,825 (8.2%) cases,
617 of 7,650 (8.1%) controls, case control OR, group 1, PSM 1, model 2 (most data in group and adjustments).
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Son et al., 30 Jul 2021, retrospective, propensity score matching, South Korea, peer-reviewed, 6 authors.
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.